Global Human Blood Plasma Fractionation Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Human Blood Plasma Fractionation Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called Blood Plasma Fractionation
Human Blood Plasma Fractionation report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Human Blood Plasma Fractionation market is projected to reach US$ 50750 million in 2029, increasing from US$ 30330 million in 2022, with the CAGR of 7.6% during the period of 2024 to 2029. Demand from Hospital and Retail Pharmacy are the major drivers for the industry.
The Blood Plasma Fractionation Product market is driven by the growing demand for plasma-derived therapies and the increasing prevalence of chronic and rare diseases. Plasma fractionation involves separating and purifying plasma components to produce therapies such as immunoglobulins, clotting factors, and albumin. The rise in awareness about the therapeutic benefits of plasma-derived products and the need for specialized treatments contribute to market growth as patients and healthcare providers seek effective solutions. Moreover, advancements in fractionation technologies, including improved product yields and safety profiles, align with better patient outcomes. However, the market also faces challenges, including ensuring a stable supply of plasma donors and addressing regulatory complexities related to plasma collection and product manufacturing. Additionally, competition from alternative therapies and addressing concerns about supply chain disruptions can pose obstacles for manufacturers. To succeed, companies must focus on research and development to offer innovative and safe plasma fractionation products, collaborate with healthcare professionals for therapeutic insights, and address the challenges to meet the increasing demand for specialized and life-saving plasma-derived therapies.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Blood Plasma Fractionation market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics
Segment by Type
Immune Globulin
Coagulation Factor
Albumin
Others
Hospital
Retail Pharmacy
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Human Blood Plasma Fractionation market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Human Blood Plasma Fractionation introduction, etc. Human Blood Plasma Fractionation Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Human Blood Plasma Fractionation market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Human Blood Plasma Fractionation report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Human Blood Plasma Fractionation market is projected to reach US$ 50750 million in 2029, increasing from US$ 30330 million in 2022, with the CAGR of 7.6% during the period of 2024 to 2029. Demand from Hospital and Retail Pharmacy are the major drivers for the industry.
The Blood Plasma Fractionation Product market is driven by the growing demand for plasma-derived therapies and the increasing prevalence of chronic and rare diseases. Plasma fractionation involves separating and purifying plasma components to produce therapies such as immunoglobulins, clotting factors, and albumin. The rise in awareness about the therapeutic benefits of plasma-derived products and the need for specialized treatments contribute to market growth as patients and healthcare providers seek effective solutions. Moreover, advancements in fractionation technologies, including improved product yields and safety profiles, align with better patient outcomes. However, the market also faces challenges, including ensuring a stable supply of plasma donors and addressing regulatory complexities related to plasma collection and product manufacturing. Additionally, competition from alternative therapies and addressing concerns about supply chain disruptions can pose obstacles for manufacturers. To succeed, companies must focus on research and development to offer innovative and safe plasma fractionation products, collaborate with healthcare professionals for therapeutic insights, and address the challenges to meet the increasing demand for specialized and life-saving plasma-derived therapies.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Blood Plasma Fractionation market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics
Segment by Type
Immune Globulin
Coagulation Factor
Albumin
Others
Segment by Application
Hospital
Retail Pharmacy
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Human Blood Plasma Fractionation market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Human Blood Plasma Fractionation introduction, etc. Human Blood Plasma Fractionation Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Human Blood Plasma Fractionation market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices